Evidence map›Paper›PMID 32083035›Full record

ArticleCanadian journal of gastroenterology & hepatology2020

Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir.

Ali Nada, Mohamed Abbasy, Aliaa Sabry, Azza Mohamed Abdu Allah, Somaia Shehab-Eldeen, Nada Elnaidany, Hanan Elimam, Kawthar Ibraheem Mohamed Ibraheem, Abdallah Essa

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Canadian journal of gastroenterology & hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Ali NadaHepatology Department, National Liver Institute, Menoufia University, Shebin-Elkom, Egypt.
Mohamed AbbasyHepatology Department, National Liver Institute, Menoufia University, Shebin-Elkom, Egypt.
Aliaa SabryHepatology Department, National Liver Institute, Menoufia University, Shebin-Elkom, Egypt.
Azza Mohamed Abdu AllahBiochemistry and Molecular Biology Department, Faculty of Medicine, Menoufia University, Shebin-Elkom, Egypt.
Somaia Shehab-EldeenTropical Medicine Department, Faculty of Medicine, Menoufia University, Shebin-Elkom, Egypt.ORCID 0000-0003-1429-0363
Nada ElnaidanyFaculty of Pharmacy, MSA University, 6th of October City, Egypt.
Hanan ElimamBiochemistry Department, Faculty of Pharmacy, University of Sadat City, Sadat City, Egypt.ORCID 0000-0003-2585-9957
Kawthar Ibraheem Mohamed IbraheemMedical Microbiology and Immunology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Abdallah EssaTropical Medicine Department, Faculty of Medicine, Menoufia University, Shebin-Elkom, Egypt.
Menoufia University · EGAin Shams University · EGOctober University of Modern Sciences and Arts · EGUniversity of Sadat City · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Direct-acting antivirals (DAAs) made a drastic change in the management of HCV infection. Sofosbuvir is one of the highly potent DAAs, eliminated mainly through the kidney. But concerns about renal safety during treatment may limit its use. Neutrophil gelatinase-associated lipocalin (NGAL) has been proven as a predictor of renal tubular injury. Hence, the aim of this work was to assess serum neutrophil gelatinase-associated lipocalin (NGAL) in HCV-positive patients before and after treatment with the sofosbuvir-based antiviral regimen. Methods: This prospective study included 87 Egyptian patients with chronic HCV infection treated with sofosbuvir plus daclatasvir with or without ribavirin for 12 weeks. Serum NGAL was measured before and at the end of treatment (EOT). Analysis of NGAL and estimated glomerular filtration rate (eGFR) evolution was done. Results: Our results showed a statistically significant decrease in serum NGAL ( Conclusions: Sofosbuvir appears to have no nephrotoxic effects and is safe to treat patients with chronic HCV infection.

Indexed as

Acute Kidney InjuryAdultAntiviral AgentsCarbamatesDrug Therapy, CombinationEgyptFemaleGlomerular Filtration RateHepacivirusHepatitis C, ChronicHumansImidazolesKidneyLipocalin-2MaleMiddle AgedAntiviral AgentsCarbamatesdaclatasvirImidazolesLCN2 protein, humanLipocalin-2PyrrolidinesRibavirinSofosbuvirValine

Identifiers

PMID32083035
PMCPMC7007947
OpenAlexW3004286118

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.